- B.S., 1983, Anhui Normal University, P.R. China
- M.S., 1986, Shanghai Medical University, P.R. China
- Ph.D., 1994, University of Toronto, Canada
- 1995-1997, University of Texas MD Anderson Cancer Center
The research in my laboratory focuses on lysophosphatidic acid (LPA) that regulates the development and progression of cancer. LPA is present in ascites of ovarian cancer patients and other malignant effusions. LPA exerts its biological functions through multiple G protein-coupled receptors (LPA1-7). Specific LPA receptors, in particular LPA2, are overexpressed in ovarian cancer and other malignancies. Recent studies indicate that LPA metabolism is also dysregulated in cancer through activation of LPA-synthesizing enzymes. We previously shown that LPA is a master regulator of expression of multiple pro-angiogenic factors such as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), interleukin (IL-6), and growth related oncogene 1 (Gro-1). These are important mediators of tumor angiogenesis and metastatic progression. Recently, we found that LPA have profound effects on cancer cell metabolism. This novel biological function of LPA is mediated though LPA2 and the downstream signaling pathways. We have developed various molecular and pharmacological strategies to study the relevance of these LPA-mediated biological functions to ovarian cancer. An ability to manipulate LPA receptors or LPA production could lead to improvement in diagnosis and treatment of human ovarian cancer.